ZURICH, Oct. 23, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), an advanced...
Hence then, the article about nls and kadimastem announce receipt of nasdaq approval merger expected to close on october 30 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 )
Also on site :
- Wall Street’s hidden recruiting pipeline isn’t an Ivy League diploma—it’s the teammate who triples your odds of getting hired
- CNN verifica: Trump afirma sin fundamento que Walz está “detrás” de ciberataque y repite falsedades en la reunión de gabinete
- ‘People can go from zero to 100’: How Gen Z is raking in $260,000 per month on a livestream auction app